Estrella Immunopharma shares are trading lower after the company announced it achieved a complete response from its first patient treated with Cd19- redirected artemis t-cells.
Portfolio Pulse from Benzinga Newsdesk
Estrella Immunopharma's shares are trading lower despite announcing a complete response from its first patient treated with Cd19-redirected artemis t-cells.
September 27, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Estrella Immunopharma's stock is trading lower despite positive clinical results from its Cd19-redirected artemis t-cells treatment.
The stock price of Estrella Immunopharma (ESLA) is declining even after the announcement of a complete response in a patient treated with their new therapy. This suggests that the market may have had higher expectations or other factors are influencing the stock negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100